Eli Lilly has inked a multi-target research and development collaboration with Massachusetts-based Remedium Bio to advance gene therapies for type 2 diabetes and obesity using Remedium’s proprietary dose-adjustable gene therapy platform.
The deal will leverage Lilly’s expertise in metabolic diseases and Remedium’s Prometheus subcutaneously administered gene delivery system to develop and commercialize one-time treatments designed to offer tunable control of therapeutic protein expression with multi-year efficacy. Remedium says the platform enables replacement of subcutaneously delivered proteins, as a safe, durable, and pharmacokinetically optimized, single injection gene therapy — for a fraction of the current treatment costs.
While the specific financials were not disclosed, Remedium will receive an upfront payment, equity investment, and potential development and commercialization milestone payments from Lilly. Remedium is also eligible to receive tiered royalties on worldwide net sales of any resulting products.
Remedium is located in Lilly Gateway Labs in Boston and is part of Lilly’s Catalyze360 model, an effort to empower early-stage biotech startups by providing access to funding as well as world-class lab space and drug development talent.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!